Cartesian Therapeutics, Inc.RNACNASDAQ
LOADING
|||
Revenue Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
51.68%
↑ 3106% above average
Average (39q)
1.61%
Historical baseline
Range
High:472.69%
Low:-296.12%
CAGR
+1.2%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 51.68% |
| Q2 2025 | -72.91% |
| Q1 2025 | 244.93% |
| Q4 2024 | -296.12% |
| Q3 2024 | -98.84% |
| Q2 2024 | 472.69% |
| Q1 2024 | -29.35% |
| Q4 2023 | 26.18% |
| Q3 2023 | 24.80% |
| Q2 2023 | -11.60% |
| Q1 2023 | -64.64% |
| Q4 2022 | -18.90% |
| Q3 2022 | -47.27% |
| Q2 2022 | 15.51% |
| Q1 2022 | 13.57% |
| Q4 2021 | 22.56% |
| Q3 2021 | 24.23% |
| Q2 2021 | 77.95% |
| Q1 2021 | -7.54% |
| Q4 2020 | 157.23% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | -100.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | -100.00% |
| Q2 2019 | 30.00% |
| Q1 2019 | -98.89% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | -100.00% |
| Q4 2017 | -37.04% |
| Q3 2017 | 3.85% |
| Q2 2017 | -81.02% |
| Q1 2017 | -95.32% |
| Q4 2016 | 179.58% |
| Q3 2016 | -48.04% |
| Q2 2016 | -3.40% |
| Q1 2016 | -2.16% |
| Q4 2015 | 32.79% |